Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IMO Schwartz stock sales may be the key that unravels this conundrum

Actually, I believe that I have answered these questions, particularly the last one.

First I suggest you revisit your numbers. What were our revenues for Q3? How many licensees, including the Js (just through Jan, since Febs numbers aren't in there)? Historical average $/licensee? Average $ per Q3 licensee, based on historical? Average $ per licensee in Q3 excluding the Js?

Keep in mind that your historical average is just that, historical. Then consider the thought that after the settlement with the Js, the bar may have been raised.

I think the answers to the above would be revealing. And I suspect you have all the base numbers and a calculator at your fingertips. Please advise.

Now, for your other question - did TPL/PTSC win against the Js?

What was TPL/PTSC's objective in entering into litigation? To get the Js to settle.

What was the Js' objective in entering litigation? To not have to settle.

Who won? I suggest it would be the litigant who met their basic objective. And, if you think about, the primary thing was to keep the patents alive.

JMHOs,

SGE

Share
New Message
Please login to post a reply